In a shocking twist for the genetic testing company 23andMe, all seven members of its board resigned at once, putting founder Anne Wojcicki’s leadership under intense scrutiny. While Wojcicki believes her startup can still be saved, the challenges ahead are significant.
A Rocky Road to Success
Founded in 2006, 23andMe initially thrived on the novelty of personal genetic testing. The company gained traction with creative marketing, including “spit parties” where people could gather to share their DNA samples. However, Wojcicki’s ambitious vision led to a series of ups and downs that ultimately put the company in jeopardy.
The Downfall of 23andMe
Despite its early excitement, 23andMe has struggled to maintain momentum. Once valued at $6 billion in 2021, the company’s worth has plummeted to under $150 million. Slowing sales, privacy concerns following a data breach, and the shutdown of its costly drug discovery division have all contributed to this decline. Wojcicki’s plan to buy back the company and take it private faced pushback from the board, leading to their collective resignation.
A Founder in Charge
Wojcicki’s leadership style has come under fire. Former employees describe her as dynamic but also controlling, with a tendency to centralize decision-making. “Is Anne happy?” reportedly became the guiding question at 23andMe, which may have slowed the company’s progress during a time when quick adaptations were crucial.
The Board’s Bold Move
The mass resignation of the board was unprecedented in the startup world. Influential figures like Neal Mohan, CEO of YouTube, and Roelof Botha, head of Sequoia Capital, expressed their disagreement with Wojcicki’s strategic direction in a public letter. The board felt that while they supported the company’s mission, Wojcicki’s approach was misguided, especially in light of the company’s declining fortunes.
Can 23andMe Be Saved?
Wojcicki remains optimistic about 23andMe’s future. She believes the company can navigate its way out of trouble, although she acknowledges the complexity of the situation. Reflecting on her leadership, she emphasizes her commitment to the company’s vision and mission. “I care about the vision and the mission,” she said, downplaying claims that she is overly controlling.
Personal Challenges and Professional Ambitions
In addition to the corporate turmoil, Wojcicki has faced personal challenges, including the loss of her sister Susan Wojcicki, former CEO of YouTube. These experiences have shaped her focus and priorities, motivating her to push for new initiatives at 23andMe, such as a lung cancer genetic study.
Looking Ahead
Despite the setbacks, 23andMe is still rolling out new products, including a report on emotional eating tendencies and partnerships to sell weight-loss drugs. However, with the board now absent, Wojcicki faces an uphill battle to regain control and build a functional leadership team.
Conclusion: A Pivotal Moment for 23andMe
The resignation of 23andMe’s entire board marks a critical juncture for the company. Wojcicki must find a way to navigate the complexities of running a publicly traded company while also addressing internal dissent. The question remains: Can she steer 23andMe back to success, or will the challenges prove insurmountable?
